Assetmark Inc. boosted its stake in shares of Genmab A/S (NASDAQ:GMAB – Free Report) by 16.2% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 82,629 shares of ...

Deutsche Bank lowered the firm’s price target on Genmab (GMAB) to DKK 2,250 from DKK 2,500 and keeps a Buy rating on the shares.

BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Biotheus, DualityBio, Fosun Pharma, Genentech, a member of the Roche ...

Now on Slide 7. As of September 30, our partners had 33 active clinical programs and approved products. During the quarter ...

Genmab A/S logged a -1.6% change during today's morning session, and is now trading at a price of $22.1 per share. The S&P ...

When it comes to developing new medicines, the Öresund region is one of the top performers in the EU. Companies working on ...

When it comes to developing new medicines, the Öresund region is one of the top performers in the EU. Companies working on ...

The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, ...

GEN1047, GEN3017, and GEN1056—to refocus resources, following its recent $1.8 billion acquisition of ProfoundBio. The move ...

TD Cowen analyst Yaron Werber has maintained their neutral stance on GMAB stock, giving a Hold rating yesterday. Yaron Werber has given his ...

An influx of late-phase programs has prompted Genmab to reassess its bets. | An influx of late-phase programs has prompted Genmab to reassess its bets. The biotech is axing three early-stage clinical ...